Lupus & antiphospholipid syndrome
Development and validation of LUPIN: a patient-centred self-administered tool to assess disease activity and patient-reported outcomes in systemic lupus erythematosus
Authors' conclusion
LUPIN effectively captures symptom domains that are often under-represented in conventional clinical indices and reflects the lived burden of disease in SLE.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE), 34 centres in metropolitan France and overseas territories (85% women, mean age 45 years)
- Participants
- 444 patients
- Comparison
- LUPIN vs physician assessments and SF-36
- Outcome
- Correlations and discordances between patient (LUPIN) and physician (SLEDAI-2K, PhGA) assessments
Methodological detailsmulticentre, physicians blinded to patients' responses
- Multicentre
- Physicians blinded to patients' responses
Performance
As reported in the abstract
LUPIN vs SLEDAI/Physician Global Assessment (PhGA): statistically significant but modest
r<0.39
LUPIN vs SF-36 fatigue
r=0.65
LUPIN vs SF-36 pain
r=0.65
LUPIN vs SF-36 physical function
r=0.69
Further findings
Correlation of LUPIN with clinical SLEDAI in active SLE (SLEDAI≥4; n=153) (subgroup)
- LUPIN vs clinical SLEDAI, p<0.0001
- r=0.53
Original publication
Development and validation of LUPIN: a patient-centred self-administered tool to assess disease activity and patient-reported outcomes in systemic lupus erythematosus. RMD Open. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →